FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387189982> ?p ?o ?g. }

• W4387189982 endingPage "50" @default.
• W4387189982 startingPage "48" @default.
• W4387189982 abstract "Introduction: Heavy menstrual blood loss or HMB ( blood loss>80ml) is one of the most common nding in peri-menopausal age group causing great inconvenience and discomfort leading to disruption in life style. Levonorgestrel containing intrauterine system ( LNG-IUS), a hormonal intrauterine contraceptive device( IUCD) as well as Ormeloxifene, a selective estrogen receptor modulator ( SERM); both are capable of reducing HMB or abnormal uterine bleeding ( AUB) and regression of endometrial hyperplasia despite side effects of their own. Aims and Objectives: To evaluate the efcacy and safety of Ormeloxifene vs LNG-IUS in medical management of HMB Methods:In this Prospective longitudinal study was done at R G Kar Medical college, Kolkata among the patients attending OPD in the Dept of Gynaecology and Obstetrics from June 2017 to Dec 2018 on 168 women of >40 years and with simple endometrial hyperplasia and abnormal uterine bleeding and was divided into two groups receiving LNG-IUS and Ormeloxifene respectively. Their outcome in terms of improvement of symptoms and regression of endometrial hyperplasia were compared. Results: Mean post-treatment haemoglobin (Hb) level (in gram/dL) in LNG-IUS group was signicantly higher than Ormeloxifene group at the end of 3rd month (11.57±1.4 vs 10.45±1.34 respectively) but not at the end of 6th month (12.01±1.11 vs 13.12±1.23 respectively). Clinically, reduction in amount and duration of bleeding in LNG-IUS group was signicantly higher than Ormeloxifene group (78.6% vs 32.1%; 76.2% vs 31% respectively). Both the incidence of amenorrhea and endometrial regression post treatment was signicantly higher in LNG-IUS group than Ormeloxifene group (73.8% vs 32.1%; 95.2% vs 76.2% respectively). Incidence of side-effect in LNG-IUS group was 60.71% compared to the same for Ormeloxifene group which was 29.76%. Conclusion: We conclude that LNG-IUS is a better option for treating HMB compared to Ormeloxifene." @default.
• W4387189982 created "2023-09-30" @default.
• W4387189982 creator A5010818461 @default.
• W4387189982 creator A5022719850 @default.
• W4387189982 creator A5030090743 @default.
• W4387189982 creator A5086261904 @default.
• W4387189982 date "2023-09-01" @default.
• W4387189982 modified "2023-09-30" @default.
• W4387189982 title "LEVONORGESTREL INTRA-UTERINE SYSTEM( LNG-IUS) VS ORMELOXIFENE ON WOMEN WITH HEAVY MENSTRUAL BLOOD LOOSS: A PROSPECTIVE LONGITUDINAL STUDY." @default.
• W4387189982 doi "https://doi.org/10.36106/ijsr/6509728" @default.
• W4387189982 hasPublicationYear "2023" @default.
• W4387189982 type Work @default.
• W4387189982 citedByCount "0" @default.
• W4387189982 crossrefType "journal-article" @default.
• W4387189982 hasAuthorship W4387189982A5010818461 @default.
• W4387189982 hasAuthorship W4387189982A5022719850 @default.
• W4387189982 hasAuthorship W4387189982A5030090743 @default.
• W4387189982 hasAuthorship W4387189982A5086261904 @default.
• W4387189982 hasConcept C10885799 @default.
• W4387189982 hasConcept C126322002 @default.
• W4387189982 hasConcept C131872663 @default.
• W4387189982 hasConcept C188816634 @default.
• W4387189982 hasConcept C2776810592 @default.
• W4387189982 hasConcept C2777689261 @default.
• W4387189982 hasConcept C2779076696 @default.
• W4387189982 hasConcept C2779234561 @default.
• W4387189982 hasConcept C2779742232 @default.
• W4387189982 hasConcept C2780186607 @default.
• W4387189982 hasConcept C2908647359 @default.
• W4387189982 hasConcept C29456083 @default.
• W4387189982 hasConcept C2986817661 @default.
• W4387189982 hasConcept C54355233 @default.
• W4387189982 hasConcept C71924100 @default.
• W4387189982 hasConcept C86803240 @default.
• W4387189982 hasConcept C99454951 @default.
• W4387189982 hasConceptScore W4387189982C10885799 @default.
• W4387189982 hasConceptScore W4387189982C126322002 @default.
• W4387189982 hasConceptScore W4387189982C131872663 @default.
• W4387189982 hasConceptScore W4387189982C188816634 @default.
• W4387189982 hasConceptScore W4387189982C2776810592 @default.
• W4387189982 hasConceptScore W4387189982C2777689261 @default.
• W4387189982 hasConceptScore W4387189982C2779076696 @default.
• W4387189982 hasConceptScore W4387189982C2779234561 @default.
• W4387189982 hasConceptScore W4387189982C2779742232 @default.
• W4387189982 hasConceptScore W4387189982C2780186607 @default.
• W4387189982 hasConceptScore W4387189982C2908647359 @default.
• W4387189982 hasConceptScore W4387189982C29456083 @default.
• W4387189982 hasConceptScore W4387189982C2986817661 @default.
• W4387189982 hasConceptScore W4387189982C54355233 @default.
• W4387189982 hasConceptScore W4387189982C71924100 @default.
• W4387189982 hasConceptScore W4387189982C86803240 @default.
• W4387189982 hasConceptScore W4387189982C99454951 @default.
• W4387189982 hasLocation W43871899821 @default.
• W4387189982 hasOpenAccess W4387189982 @default.
• W4387189982 hasPrimaryLocation W43871899821 @default.
• W4387189982 hasRelatedWork W153466153 @default.
• W4387189982 hasRelatedWork W1999569870 @default.
• W4387189982 hasRelatedWork W2007561870 @default.
• W4387189982 hasRelatedWork W2020018138 @default.
• W4387189982 hasRelatedWork W2051230413 @default.
• W4387189982 hasRelatedWork W2123407255 @default.
• W4387189982 hasRelatedWork W2735377277 @default.
• W4387189982 hasRelatedWork W2963281299 @default.
• W4387189982 hasRelatedWork W3082043237 @default.
• W4387189982 hasRelatedWork W4295901522 @default.
• W4387189982 isParatext "false" @default.
• W4387189982 isRetracted "false" @default.
• W4387189982 workType "article" @default.